Buprenorphine Microdosing Cross Tapers: A Time for Change
International Journal of Environmental Research and Public Health December 8, 2022 Amer Raheemullah, Ori-Michael Benhamou, Jamie Kuo et al.
Buprenorphine is a partial opioid agonist that is Food and Drug Administration (FDA) approved to treat chronic pain and opioid use disorder (OUD). The national prescribing guidelines in the United States (US) recommend that patients transitioning from full opioid agonists to buprenorphine first undergo 12 or more hours of active opioid withdrawal, in order to avoid buprenorphine-precipitated...